Back to search results

SBRT with atezolizumab and bevacizumab for liver cancer

This study is testing a combination treatment for hepatocellular carcinoma (HCC), a type of liver cancer. It combines Stereotactic Body Radiotherapy (SBRT), a precise form of radiation, with two medications: atezolizumab and bevacizumab. The study is for people aged 18 to 99 whose HCC cannot be treated with surgery or ablation, and who need systemic therapy. Researchers want to see how well this combination works over three years. The study plans to enroll 18 participants, but its current status is unclear.

Study design
This is a Phase 1 study, which means it's an early study to test safety and dosage. It will involve a small number of participants, with a planned enrollment of 18 people.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of the study will be measured at 3 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05488522

SBRT With Atezo/Bev for HCC

Recruiting
PHASE1Ages 18–99InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~18 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:SBRT + atezolizumab and bevacizumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Objective
Measured over 3 years

Conditions

Hepatocellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT05488522

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Edgar Ben-Josef, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center

Who to contact

Edgar Ben-Josef, MD
[email protected]
215-615-6767
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated.

What this trial measures

  • Primary Objective3 years

    we will measure the total number of subjects that can tolerate the recommended phase II regimen of SBRT with atezolizumab/bevacizumab (atezo/bev) in patients with advanced hepatocellular carcinoma and the proportion of patients experiencing a radiation-attributable DLT at each dose level.